EICHOR
● Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Condition: Polymyositis, Dermatomyositis · Sponsor: AstraZeneca
About this study
The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) \[polymyositis (PM) or dermatomyositis (DM)\] while receiving standard of care (SoC) treatment.
This description comes directly from the study's public registry record.
Talk to the study team
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
Locations (236)
| Research Site | Phoenix, Arizona, United States | Not Yet Recruiting |
| Research Site | Irvine, California, United States | Recruiting |
| Research Site | Aurora, Colorado, United States | Recruiting |
| Research Site | Denver, Colorado, United States | Not Yet Recruiting |
| Research Site | New Haven, Connecticut, United States | Recruiting |
| Research Site | Washington D.C., District of Columbia, United States | Withdrawn |
| Research Site | Boca Raton, Florida, United States | Recruiting |
| Research Site | Boynton Beach, Florida, United States | Withdrawn |
| Research Site | Gainesville, Florida, United States | Withdrawn |
| Research Site | Margate, Florida, United States | Suspended |
| Research Site | Miami, Florida, United States | Withdrawn |
| Research Site | Miami, Florida, United States | Recruiting |
+ 224 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06455449